CY2016040I1 - Επιλογες θεραπειας για τη νοσο του fabry - Google Patents

Επιλογες θεραπειας για τη νοσο του fabry

Info

Publication number: CY2016040I1
Authority: CY; Cyprus
Prior art keywords: fabry; disease; treatment options; options; treatment
Prior art date: 2006-05-16

Application number

CY2016040C

Other languages

English (en)

Other versions

CY2016040I2 (el

Original Assignee

Amicus Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-16

Filing date

2016-11-15

Publication date

2017-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016040(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-15 Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.

2017-06-28 Publication of CY2016040I2 publication Critical patent/CY2016040I2/el

2017-06-28 Publication of CY2016040I1 publication Critical patent/CY2016040I1/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Ecology (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CY2016040C 2006-05-16 2016-11-15 Επιλογες θεραπειας για τη νοσο του fabry CY2016040I1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80108906P	2006-05-16	2006-05-16
US85363106P	2006-10-23	2006-10-23
EP07797506.8A EP2024745B1 (en)	2006-05-16	2007-05-16	Assays for diagnosing and evaluating treatment options for fabry disease

Publications (2)

Publication Number	Publication Date
CY2016040I2 CY2016040I2 (el)	2017-06-28
CY2016040I1 true CY2016040I1 (el)	2017-06-28

Family

ID=38723987

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20141100377T CY1115180T1 (el)	2006-05-16	2014-05-27	Επιλογες θεραπειας για τη νοσο του fabry
CY20161100448T CY1117656T1 (el)	2006-05-16	2016-05-24	Επιλογες θεραπειας για τη νοσο του fabry
CY2016040C CY2016040I1 (el)	2006-05-16	2016-11-15	Επιλογες θεραπειας για τη νοσο του fabry

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20141100377T CY1115180T1 (el)	2006-05-16	2014-05-27	Επιλογες θεραπειας για τη νοσο του fabry
CY20161100448T CY1117656T1 (el)	2006-05-16	2016-05-24	Επιλογες θεραπειας για τη νοσο του fabry

Country Status (19)

Country	Link
US (9)	US7851143B2 (el)
EP (6)	EP2024745B1 (el)
JP (7)	JP2009537149A (el)
AU (1)	AU2007253900A1 (el)
CA (1)	CA2652553C (el)
CY (3)	CY1115180T1 (el)
DK (3)	DK3457135T3 (el)
ES (4)	ES2573498T3 (el)
FI (1)	FI3457135T3 (el)
HK (1)	HK1218955A1 (el)
HU (3)	HUE027569T2 (el)
LT (2)	LT3457135T (el)
LU (1)	LU93312I2 (el)
MX (2)	MX351004B (el)
NL (1)	NL300843I2 (el)
PL (3)	PL2533050T6 (el)
PT (2)	PT3457135T (el)
SI (3)	SI2533050T1 (el)
WO (1)	WO2007137072A2 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2024745B1 (en)	2006-05-16	2015-07-08	Amicus Therapeutics, Inc.	Assays for diagnosing and evaluating treatment options for fabry disease
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
MX2009011473A (es) *	2007-04-26	2010-01-18	Amicus Therapeutics Inc	Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
SI2252313T1 (sl) *	2008-02-12	2015-08-31	Amicus Therapeutics, Inc.	Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA2718059A1 (en) *	2008-03-12	2009-09-17	Amicus Therapeutics, Inc.	Assays for diagnosing and evaluating treatment options for pompe disease
EP3028701B1 (en) *	2009-11-17	2019-11-13	Baylor Research Institute	1-deoxygalactonojirimycin for use in treating a cardiac disease
AU2011223706A1 (en) *	2010-03-05	2012-09-20	Baylor Research Institute	Involvement of androgen/androgen receptor pathway in Fabry disease
EA031874B1 (ru) *	2011-03-11	2019-03-29	Амикус Терапьютикс, Инк.	Способ лечения болезни фабри
PT2707101T (pt)	2011-05-12	2019-05-30	Proteostasis Therapeutics Inc	Reguladores da proteostase
AU2012359165A1 (en) *	2011-12-22	2014-07-10	Centogene Ip Gmbh	Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
CA2861464C (en)	2012-01-25	2018-03-06	Proteostasis Therapeutics, Inc.	Proteasome activity modulating tricyclic compounds
WO2014127038A1 (en) *	2013-02-12	2014-08-21	Baylor Research Institute	Methods and compositions related to calcium homeostasis and fabry disease
MX374840B (es) *	2013-12-23	2025-03-06	Bcn Peptides Sa	Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis.
US9675627B2 (en) *	2014-04-14	2017-06-13	Amicus Therapeutics, Inc.	Dosing regimens for treating and/or preventing cerebral amyloidoses
CN107074971B (zh) *	2014-07-25	2021-11-02	夏尔人类遗传性治疗公司	人4-磷酸衔接蛋白2糖脂转移蛋白样域的晶体结构
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
TWI875676B (zh) *	2016-07-19	2025-03-11	美商阿米庫斯醫療股份有限公司	治療ert初治的和已經歷ert的患者中之法布瑞氏症
US12020820B1 (en)	2017-03-03	2024-06-25	Cerner Innovation, Inc.	Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en)	2017-03-06	2022-05-17	Cerner Innovation, Inc.	Predicting glycogen storage diseases (Pompe disease) and decision support
EP4374918B1 (en) *	2017-05-30	2025-07-16	Amicus Therapeutics, Inc.	Methods of treating fabry patients having renal impairment
KR20240017111A (ko)	2017-05-30	2024-02-06	아미쿠스 세라퓨틱스, 인코포레이티드	신장 손상을 갖는 파브리 환자를 치료하는 방법
US11923048B1 (en)	2017-10-03	2024-03-05	Cerner Innovation, Inc.	Determining mucopolysaccharidoses and decision support tool
LT3749308T (lt) *	2018-02-06	2024-02-12	Amicus Therapeutics, Inc.	Klasikine fabri liga sergančių pacientų gydymas migalastatu
WO2019157047A1 (en)	2018-02-06	2019-08-15	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
BR112020026580A2 (pt)	2018-06-27	2021-03-23	Proteostasis Therapeutics, Inc. (Fem)	Compostos, composição farmacêutica e métodos para tratar um paciente
WO2020006269A1 (en)	2018-06-27	2020-01-02	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
WO2020023390A1 (en)	2018-07-25	2020-01-30	Modernatx, Inc.	Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
BR112022002202A2 (pt)	2019-08-07	2022-06-14	Amicus Therapeutics Inc	Métodos de tratar doença de fabry em pacientes tendo uma mutação no gene gla
US11191827B1 (en)	2020-12-09	2021-12-07	Tevogen Bio Inc.	COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en)	2020-12-16	2023-04-11	Amicus Therapeutics, Inc.	Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0463109A4 (en) *	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
EP0536402A4 (en)	1990-06-29	1993-05-12	Nippon Shinyaku Company, Limited	Piperidine derivative
US6270954B1 (en)	1996-04-10	2001-08-07	The Regents Of The University Of California	Correction of genetic defects using chemical chaperones
JP2000509971A (ja) *	1996-04-10	2000-08-08	ザリージェンツオブザユニバーシティオブカリフォルニア	化学的シャペローンを用いる遺伝的欠陥の修正
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en)	2001-10-09	2010-11-30	Oregon Health & Science University	Method for pharmacoperones correction of GnRHR mutant protein misfolding
WO2004069190A2 (en)	2003-01-31	2004-08-19	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiency disorders
US7446098B2 (en) *	2003-02-18	2008-11-04	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiencies
US20070066543A1 (en) *	2003-05-22	2007-03-22	The Hospital For Sick Children	Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr)	2003-11-07	2008-01-18	Centre Nat Rech Scient	Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
BRPI0416216A (pt)	2003-11-12	2006-12-26	Amicus Therapeutics Inc	composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
EP3441090A1 (en)	2005-05-17	2019-02-13	Amicus Therapeutics, Inc.	A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
MX2007015602A (es)	2005-06-08	2008-02-21	Amicus Therapeutics Inc	Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas.
PT2027137E (pt)	2005-06-08	2015-06-09	Amicus Therapeutics Inc	Purificação de imino e amino-açúcares
AU2006272497B2 (en)	2005-07-27	2012-07-19	University Of Florida Research Foundation, Inc.	Small compounds that correct protein misfolding and uses thereof
WO2007089591A2 (en)	2006-01-27	2007-08-09	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for high throughput screening of pharmacological chaperones
EP2024745B1 (en)	2006-05-16	2015-07-08	Amicus Therapeutics, Inc.	Assays for diagnosing and evaluating treatment options for fabry disease
WO2008034628A1 (en)	2006-09-22	2008-03-27	Krka, Tovarna Zdravil, D.D., Novo Mesto	Aripiprazole hemifumarate and process for its preparation
JP2010523578A (ja)	2007-03-30	2010-07-15	アミカスセラピューティックスインコーポレイテッド	薬理シャペロンを用いるファブリー病の治療方法
MX2009011473A (es)	2007-04-26	2010-01-18	Amicus Therapeutics Inc	Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI2252313T1 (sl)	2008-02-12	2015-08-31	Amicus Therapeutics, Inc.	Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
WO2010048532A1 (en)	2008-10-24	2010-04-29	Amicus Therapeutics, Inc.	Multiple compartment dosing model
US9206457B2 (en)	2009-05-26	2015-12-08	Amicus Therapeutics, Inc.	Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US20110070643A1 (en)	2009-05-26	2011-03-24	Do Hung V	Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
EP3028701B1 (en)	2009-11-17	2019-11-13	Baylor Research Institute	1-deoxygalactonojirimycin for use in treating a cardiac disease
EA031874B1 (ru)	2011-03-11	2019-03-29	Амикус Терапьютикс, Инк.	Способ лечения болезни фабри
US10155027B2 (en)	2012-07-17	2018-12-18	Amicus Therapeutics, Inc.	Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014014938A1 (en)	2012-07-17	2014-01-23	Amicus Therapeutics, Inc.	Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
EP3432882B1 (en)	2016-03-22	2021-09-01	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
TWI875676B (zh)	2016-07-19	2025-03-11	美商阿米庫斯醫療股份有限公司	治療ert初治的和已經歷ert的患者中之法布瑞氏症
TW201829770A (zh)	2017-01-10	2018-08-16	美商阿米庫斯醫療股份有限公司	用於治療fabry氏病之重組α-半乳糖苷酶A
KR20240017111A (ko)	2017-05-30	2024-02-06	아미쿠스 세라퓨틱스, 인코포레이티드	신장 손상을 갖는 파브리 환자를 치료하는 방법
SG11202000423XA (en)	2017-07-19	2020-02-27	Amicus Therapeutics Inc	Treatment of fabry disease in ert-naïve and ert-experienced patients
PL4176877T3 (pl)	2017-08-28	2025-04-07	Amicus Therapeutics, Inc.	Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego
LT3749308T (lt)	2018-02-06	2024-02-12	Amicus Therapeutics, Inc.	Klasikine fabri liga sergančių pacientų gydymas migalastatu
WO2019157047A1 (en)	2018-02-06	2019-08-15	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
SI3840753T1 (sl)	2018-08-20	2025-01-31	Amicus Therapeutics, Inc.	Migalastat za uporabo v postopkih zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA
MX2021015352A (es)	2019-06-11	2022-04-06	Amicus Therapeutics Inc	Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
BR112022002202A2 (pt)	2019-08-07	2022-06-14	Amicus Therapeutics Inc	Métodos de tratar doença de fabry em pacientes tendo uma mutação no gene gla

2007
- 2007-05-16 EP EP07797506.8A patent/EP2024745B1/en active Active
- 2007-05-16 HU HUE14168748A patent/HUE027569T2/en unknown
- 2007-05-16 PT PT181971359T patent/PT3457135T/pt unknown
- 2007-05-16 LT LTEP18197135.9T patent/LT3457135T/lt unknown
- 2007-05-16 EP EP14168748.3A patent/EP2787345B8/en active Active
- 2007-05-16 JP JP2009511222A patent/JP2009537149A/ja active Pending
- 2007-05-16 SI SI200731457T patent/SI2533050T1/sl unknown
- 2007-05-16 ES ES14168748.3T patent/ES2573498T3/es active Active
- 2007-05-16 DK DK18197135.9T patent/DK3457135T3/da active
- 2007-05-16 SI SI200732206T patent/SI3457135T1/sl unknown
- 2007-05-16 ES ES12168451.8T patent/ES2464527T7/es active Active
- 2007-05-16 PL PL12168451T patent/PL2533050T6/pl unknown
- 2007-05-16 SI SI200731776A patent/SI2787345T1/sl unknown
- 2007-05-16 PL PL18197135.9T patent/PL3457135T3/pl unknown
- 2007-05-16 HU HUE18197135A patent/HUE071237T2/hu unknown
- 2007-05-16 PT PT121684518T patent/PT2533050E/pt unknown
- 2007-05-16 ES ES15173515T patent/ES2709445T3/es active Active
- 2007-05-16 AU AU2007253900A patent/AU2007253900A1/en not_active Abandoned
- 2007-05-16 MX MX2013006681A patent/MX351004B/es unknown
- 2007-05-16 ES ES18197135T patent/ES3012794T3/es active Active
- 2007-05-16 EP EP24217103.1A patent/EP4541418A3/en active Pending
- 2007-05-16 MX MX2008014679A patent/MX2008014679A/es active IP Right Grant
- 2007-05-16 EP EP18197135.9A patent/EP3457135B1/en active Active
- 2007-05-16 DK DK14168748.3T patent/DK2787345T3/en active
- 2007-05-16 EP EP15173515.6A patent/EP2955520B1/en active Active
- 2007-05-16 EP EP12168451.8A patent/EP2533050B3/en active Active
- 2007-05-16 CA CA2652553A patent/CA2652553C/en active Active
- 2007-05-16 US US11/749,512 patent/US7851143B2/en active Active
- 2007-05-16 PL PL14168748T patent/PL2787345T3/pl unknown
- 2007-05-16 WO PCT/US2007/069046 patent/WO2007137072A2/en not_active Ceased
- 2007-05-16 DK DK12168451.8T patent/DK2533050T6/da active
- 2007-05-16 FI FIEP18197135.9T patent/FI3457135T3/fi active
2010
- 2010-12-13 US US12/966,904 patent/US20110104727A1/en not_active Abandoned
2012
- 2012-04-12 US US13/445,338 patent/US9000011B2/en active Active
- 2012-12-27 JP JP2012285265A patent/JP6026268B2/ja active Active
2014
- 2014-05-27 CY CY20141100377T patent/CY1115180T1/el unknown
2015
- 2015-03-09 US US14/641,707 patent/US9480682B2/en active Active
- 2015-07-31 JP JP2015151795A patent/JP2016006088A/ja not_active Withdrawn
2016
- 2016-05-24 CY CY20161100448T patent/CY1117656T1/el unknown
- 2016-06-15 HK HK16106878.6A patent/HK1218955A1/en unknown
- 2016-10-31 US US15/338,923 patent/US9987263B2/en active Active
- 2016-11-11 NL NL300843C patent/NL300843I2/nl unknown
- 2016-11-15 CY CY2016040C patent/CY2016040I1/el unknown
- 2016-11-16 LU LU93312C patent/LU93312I2/fr unknown
- 2016-11-16 LT LTPA2016033C patent/LTC2787345I2/lt unknown
- 2016-11-16 HU HUS1600048C patent/HUS1600048I1/hu unknown
2018
- 2018-04-10 JP JP2018075570A patent/JP6800176B2/ja active Active
- 2018-05-08 US US15/974,217 patent/US10383864B2/en active Active
- 2018-05-08 US US15/974,222 patent/US10406143B2/en active Active - Reinstated
2019
- 2019-09-09 US US16/564,694 patent/US11241422B2/en active Active
2020
- 2020-07-27 JP JP2020126185A patent/JP7175297B2/ja active Active
2022
- 2022-02-07 US US17/665,969 patent/US20220160690A1/en active Pending
- 2022-11-08 JP JP2022178697A patent/JP2023027053A/ja active Pending
2024
- 2024-12-13 JP JP2024218337A patent/JP2025060691A/ja active Pending

Also Published As

Publication number	Publication date
ES2464527T7 (es)	2015-09-14
US20170042868A1 (en)	2017-02-16
EP2533050B3 (en)	2015-06-24
EP2024745A4 (en)	2010-03-17
EP3457135B1 (en)	2024-12-04
EP4541418A2 (en)	2025-04-23
SI3457135T1 (sl)	2025-07-31
AU2007253900A1 (en)	2007-11-29
JP2023027053A (ja)	2023-03-01
JP2016006088A (ja)	2016-01-14
US20180325881A1 (en)	2018-11-15
JP6800176B2 (ja)	2020-12-16
MX351004B (es)	2017-09-26
CY1117656T1 (el)	2017-05-17
MX2008014679A (es)	2009-04-14
EP2787345B8 (en)	2016-04-13
US7851143B2 (en)	2010-12-14
LU93312I2 (fr)	2017-01-26
ES2464527T3 (es)	2014-06-03
HK1129458A1 (en)	2009-11-27
US9987263B2 (en)	2018-06-05
ES3012794T3 (en)	2025-04-10
CA2652553C (en)	2020-08-18
JP2009537149A (ja)	2009-10-29
EP2533050A1 (en)	2012-12-12
ES2709445T3 (es)	2019-04-16
PL3457135T3 (pl)	2025-06-09
PL2533050T6 (pl)	2016-05-31
US10383864B2 (en)	2019-08-20
US20180250279A1 (en)	2018-09-06
ES2573498T3 (es)	2016-06-08
PT2533050E (pt)	2014-05-26
DK3457135T3 (da)	2025-02-24
HK1178975A1 (en)	2013-09-19
US20190388409A1 (en)	2019-12-26
EP2955520B1 (en)	2018-10-31
HK1218955A1 (en)	2017-03-17
US20150238474A1 (en)	2015-08-27
EP2787345B1 (en)	2016-02-24
PL2787345T3 (pl)	2016-08-31
CA2652553A1 (en)	2007-11-29
JP2025060691A (ja)	2025-04-10
JP6026268B2 (ja)	2016-11-16
HUE027569T2 (en)	2016-10-28
WO2007137072A2 (en)	2007-11-29
CY1115180T1 (el)	2016-12-14
EP3457135A1 (en)	2019-03-20
LT3457135T (lt)	2025-05-12
EP2024745B1 (en)	2015-07-08
HUS1600048I1 (hu)	2017-01-30
US10406143B2 (en)	2019-09-10
EP2955520A1 (en)	2015-12-16
US9000011B2 (en)	2015-04-07
DK2533050T3 (da)	2014-06-02
LTPA2016033I1 (lt)	2016-12-12
EP2024745A2 (en)	2009-02-18
JP2020196717A (ja)	2020-12-10
PL2533050T3 (pl)	2014-08-29
US20120220632A1 (en)	2012-08-30
DK2787345T3 (en)	2016-05-30
JP2018138564A (ja)	2018-09-06
US20110104727A1 (en)	2011-05-05
DK2533050T6 (da)	2015-09-21
ES2464527T9 (es)	2015-07-24
FI3457135T3 (fi)	2025-03-08
HUE071237T2 (hu)	2025-08-28
US9480682B2 (en)	2016-11-01
US20220160690A1 (en)	2022-05-26
PT3457135T (pt)	2025-02-04
WO2007137072A3 (en)	2008-10-16
US20080056994A1 (en)	2008-03-06
EP4541418A3 (en)	2025-07-09
SI2787345T1 (sl)	2016-08-31
US11241422B2 (en)	2022-02-08
LTC2787345I2 (lt)	2017-10-10
JP7175297B2 (ja)	2022-11-18
CY2016040I2 (el)	2017-06-28
NL300843I2 (el)	2016-12-21
EP2787345A1 (en)	2014-10-08
SI2533050T1 (sl)	2014-07-31
EP2533050B1 (en)	2014-03-12
JP2013100307A (ja)	2013-05-23

Publication	Publication Date	Title
CY2016040I1 (el)	2017-06-28	Επιλογες θεραπειας για τη νοσο του fabry
BRPI0810646A2 (pt)	2014-11-04	" compostos farmacêuticos ".
EP1868459A4 (en)	2010-01-27	FUNCTIONAL SHOE
DE602005026825D1 (de)	2011-04-21	Endoskop
DE602005026235D1 (de)	2011-03-24	Kapsel-endoskop
DE602005027052D1 (de)	2011-05-05	Endoskopbehandlungssystem
NL1029015A1 (nl)	2005-11-15	Therapeutische verbindingen.
EP1903866A4 (en)	2010-12-22	IMPROVED RELEASE OF TETRAHYDROCANNABINOL
DE602006004866D1 (de)	2009-03-05	Katheter
EP1751652A4 (en)	2010-06-02	MONITOR DEVICE
EP1908389A4 (en)	2011-03-02	MEDICAL CONTROLLER
DK1733707T3 (da)	2008-11-10	Infusionskanylesystem
NO20070251A (no)	2007-03-12	Brønnbehandling
NO20070297A (no)	2007-03-12	Brønnbehandling
DE602004021940D1 (de)	2009-08-20	Endoskopsystem
DE602005017840D1 (de)	2010-01-07	Blutdruckmonitor
HRP20160866T1 (hr)	2016-10-07	Postupci primjene hipoglikemijskih sredstava
DK2035369T3 (da)	2014-10-06	Terapeutiske
FR2898636B1 (fr)	2012-05-18	Structure de queue-d'aronde de soufflante.
BRPI0808246A2 (pt)	2018-10-30	"fralda descartável".
EP2052757A4 (en)	2009-12-02	MEDICAL CAPSULE
DK1863899T3 (da)	2013-10-14	Hudbehandlingspræparater
BRPI0716374A2 (pt)	2016-05-10	"dispositivos médicos"
DE602006016764D1 (de)	2010-10-21	Medizinisches Telemetriesystem
DE602005026124D1 (de)	2011-03-10	Endoskop